Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation
Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation
复制标题
DOI：
10.1002/cyto.b.21050
复制
发表时间：
2013-01-01
影响因子：
3.4
通讯作者：
Colovai, Adriana I.
中科院分区：
文献类型：
--
作者：
Dobrowolska, Hanna;Gill, Kamraan Z.;Colovai, Adriana I.
背景：由于缺乏高度敏感和特异性的单核细胞标志物，对伴有单核细胞分化的AML的诊断受到限制。免疫球蛋白样转录物3（ILT 3）是由骨髓单核细胞表达的免疫抑制性受体，并且在致耐受性树突状细胞中以高水平表达。方法：采用流式细胞术检测37例AML患者和20例未检测到疾病的AML患者IL-3的表达。结果如下：我们发现ILT 3在所有显示单核细胞分化的AML病例中表达（FAB M4/M5; N = 18），但在AML M1/M2和M3中不表达（N = 19; P < 0.0001）。在单核细胞白血病中观察到ILT 3和未成熟细胞标志物如CD 34和CD 117的共表达。在患有难治性或复发性疾病的M4/M5患者中，ILT 3表达在治疗后得以保留。ILT 3表达与存在与中等预后相关的细胞遗传学异常相关（P = 0.001）。罕见的CD 45 dimCD 34 + CD 117 + ILT 3+细胞在非受累骨髓中被鉴定，表明ILT 3表达是由正常的骨髓单核细胞前体细胞在早期获得的。结论：ILT 3是一种高度敏感和特异的鉴别单核细胞分化型AML与其他类型AML的标志物。ILT 3表达的检测应纳入AML患者的初始诊断检查和监测。(c)2012年国际临床细胞计数学会
Background: The diagnosis of AML with monocytic differentiation is limited by the lack of highly sensitive and specific monocytic markers. Immunoglobulin-like transcript 3 (ILT3) is an immune inhibitory receptor expressed by myelomonocytic cells and at high levels by tolerogenic dendritic cells. Methods: Using flow cytometry, we analyzed the expression of ILT3 in 37 patients with AML and 20 patients with no detectable disease. Results: We showed that ILT3 was expressed in all cases of AML displaying monocytic differentiation (FAB M4/M5; N = 18), but not in AML M1/M2 and M3 (N = 19; P < 0.0001). Co-expression of ILT3 and immature cell markers, such as CD34 and CD117, was observed in monoblastic leukemia. ILT3 expression was preserved after treatment in M4/M5 patients with refractory or relapsed disease. ILT3 expression was associated with the presence of cytogenetic abnormalities linked to an intermediate prognosis (P = 0.001). Rare CD45dimCD34+CD117+ILT3+ cells were identified in noninvolved bone marrow, suggesting that ILT3 expression is acquired at an early stage by normal myelomonocytic precursors. Conclusions: ILT3 is a highly sensitive and specific marker which distinguishes AML with monocytic differentiation from other types of AML. Testing of ILT3 expression should be incorporated into the initial diagnostic work-up and monitoring of patients with AML. (c) 2012 International Clinical Cytometry Society